Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sage Therapeutics, Inc.    SAGE

SAGE THERAPEUTICS, INC.

(SAGE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/14/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
68.08(c) 68.61(c) 69.03(c) 70.38(c) 69.67 Last
450 647 1 020 061 658 578 498 069 88 620 Volume
+0.06% +0.78% +0.61% +1.96% -1.01% Change
More quotes
Financials (USD)
Sales 2019 8,74 M
EBIT 2019 -728 M
Net income 2019 -700 M
Finance 2019 977 M
Yield 2019 -
Sales 2020 67,0 M
EBIT 2020 -776 M
Net income 2020 -741 M
Finance 2020 773 M
Yield 2020 -
P/E ratio 2019 -5,12x
P/E ratio 2020 -5,19x
EV / Sales2019 306x
EV / Sales2020 42,9x
Capitalization 3 647 M
More Financials
Company
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid... 
More about the company
Surperformance© ratings of Sage Therapeutics, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on SAGE THERAPEUTICS, INC.
02/10SAGE THERAPEUTICS : to Report Fourth Quarter and Full Year 2019 Financial Result..
BU
02/05SAGE THERAPEUTICS : Announces Inducement Grants Under NASDAQ Listing Rule 5635
AQ
02/04SAGE THERAPEUTICS : Announces Inducement Grants Under NASDAQ Listing Rule 5635(c..
BU
01/06SAGE THERAPEUTICS : Announces Inducement Grants Under NASDAQ Listing Rule 5635(4..
AQ
01/03SAGE THERAPEUTICS : Announces Inducement Grants Under NASDAQ Listing Rule 5635(c..
BU
2019SAGE THERAPEUTICS : to Present at J.P. Morgan Healthcare Conference on Monday, J..
BU
2019SAGE THERAPEUTICS : Announces Planned Progression of SAGE-718 to Phase 2 in Hunt..
AQ
2019SAGE THERAPEUTICS : HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Sage The..
PR
2019SAGE THERAPEUTICS : Announces Planned Progression of SAGE-718 to Phase 2 in Hunt..
BU
2019ALPHABET, CAMPBELL, EXPEDIA : Stocks That Defined the Week
DJ
2019SAGE THERAPEUTICS : Lost Money in Sage Therapeutics, Inc.?
BU
2019Kroger, Sage take losses while Five Below, Acadia advance
AQ
2019SAGE THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form ..
AQ
2019SAGE THERAPEUTICS : Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study ..
BU
2019SAGE THERAPEUTICS : Announces Inducement Grants Under NASDAQ Listing Rule 5635(4..
AQ
More news
News in other languages on SAGE THERAPEUTICS, INC.
2019Wall Street finit en hausse après une séance hésitante
2019SAGE THERAPEUTICS, INC. : massacre en vue à Wall Street
2019AVIS D'ANALYSTES DU JOUR : Air France, BNP Paribas, Teleperformance, DBV Technol..
2019STOCK MARKET PARIS : La Fed choisit la sobriété
2019STOCK MARKET PARIS : Et si l'Allemagne aidait la BCE à relancer la croissance ?
More news
Analyst Recommendations on SAGE THERAPEUTICS, INC.
More recommendations
Sector news : Biotechnology & Medical Research - NEC
02/20Anglo American Discloses All Mine Deaths in Industry Shift--Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift -- Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift
DJ
02/20GlaxoSmithKline Invests $50 Million in Biotech Startup's Cell-Therapy Program
DJ
02/19Five Prime Therapeutics In License Agreement with Seattle Genetics
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart SAGE THERAPEUTICS, INC.
Duration : Period :
Sage Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAGE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 107,43  $
Last Close Price 70,38  $
Spread / Highest target 223%
Spread / Average Target 52,6%
Spread / Lowest Target -14,7%
EPS Revisions
Managers
NameTitle
Jeffrey M. Jonas President, Chief Executive Officer & Director
Kevin Paul Starr Chairman
Kimi E. Iguchi Chief Financial Officer & Treasurer
Albert J. Robichaud Chief Scientific Officer
James Doherty Chief Research Officer
Sector and Competitors
1st jan.Capitalization (M$)
SAGE THERAPEUTICS, INC.-2.51%3 647
LONZA GROUP19.03%31 732
IQVIA HOLDINGS INC.6.23%31 649
SEATTLE GENETICS, INC.3.56%20 383
CELLTRION, INC.--.--%19 812
INCYTE CORPORATION-5.61%17 943